SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Shattuck Labs is conducting an underwritten public offering of 10.9 million common shares and 7.9 million pre-funded warrants with representatives including Leerink Partners, J.P. …
NXP's board approved a quarterly dividend of $1.014 per ordinary share, payable July 9, 2026, reflecting confidence in the company's strong capital structure and cash generation. T…
Nakamoto Inc. paid down $45 million in debt by selling ~600 Bitcoin, entered new loan terms extending $105 million to June 2027, and authorized a $25 million share repurchase progr…
Spark I Acquisition Corporation signed a merger agreement with ZincFive Inc, effective June 11, 2026, combining the SPAC with the target company. The transaction involves conversio…
Theriva Biologics published Phase 1 clinical trial results demonstrating that VCN-01 oncolytic adenovirus combined with durvalumab produced prolonged overall survival in heavily pr…
Enliven Therapeutics announced updated positive Phase 1 data for ELVN-001 in chronic myeloid leukemia with 61% overall response rates and FDA alignment on the 80 mg dose for the pi…
J.W. Mays reported nine-month revenues of $15.8M versus $16.8M year-ago, with net losses widening to $1.1M versus $44K losses in the prior period. The retailer faces ongoing operat…
InspireMD announced positive 30-day results from CGUARDIANS II trial showing 100% acute device success with zero major adverse events for its CGuard Prime 80cm stent in TCAR proced…
Caribou Biosciences reported long-term data for vispa-cel CAR-T therapy showing 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patien…
Vera Bradley achieved its first quarter of overall revenue growth since Q4 FY22, with net revenues growing 7.8% year-over-year and non-GAAP gross margin expansion of 430 basis poin…
Prairie Operating Co. executed a second amendment to its credit agreement effective April 1, 2026, redetermining and reaffirming its borrowing base at $475 million with Citibank as…
Atossa Therapeutics has issued common stock purchase warrants exercisable beginning December 12, 2026, with terms defined in a June 10, 2026 Securities Purchase Agreement. The warr…
Rafael Holdings completed enrollment in its pivotal Phase 3 TransportNPC trial for Niemann-Pick disease Type C and expects to submit an NDA in the second half of 2026 following a p…
Silence Therapeutics presented Phase 1 follow-up data showing divesiran reduced phlebotomy requirements from 80 procedures to 5 during treatment, with benefits persisting post-dose…
Driven Brands reported first-quarter revenue of $484.4 million with 2% same-store sales growth and improved net leverage to 3.2x Adjusted EBITDA. The company reiterated full-year 2…
Xeris Biopharma agreed to retire approximately $23 million of 8.00% Convertible Senior Notes due 2028 through private exchanges, reducing annual interest expenses by roughly $2 mil…
McGraw Hill reported fiscal year 2026 revenue of $2.1B with recurring revenue up 5.8% and returned to profitability with $35.3M net income. The company is positioned for accelerate…
Nurix Therapeutics announced updated Phase 1a/b clinical trial results showing a 92.9% objective response rate in second-line CLL patients treated with bexobrutideg, with durable r…
C4 Therapeutics released a corporate presentation showcasing its TORPEDO platform and protein degradation technology for disease treatment. The filing contains standard forward-loo…
Orthofix Medical amended its Second Amended and Restated Stock Purchase Plan to increase the total reserved shares to 6,100,000. The expansion provides the company with additional …